UNDERSTANDING THE MAZE OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA

A multiple myeloma diagnosis can feel like navigating a maze because patients go down paths with periods of remission and turns of relapse throughout the course of the disease.

Out Of The 230,000, the number of people living with multiple myeloma around the world...

77,000 people are living with relapsed and refractory multiple myeloma (RRMM) 1

Treating RRMM presents unique challenges.

Patients with RRMM typically are:

Older

Show more symptoms, with potential comorbidities (having two disorders at once)

Resistant to treatment

The facts are:

39.0% of transplant patients

37.4% of non-transplant patients

Relapse between one to five years of first-line therapy 2

Researchers are working hard to bring treatment advancements to patients living with RRMM

Refractory and relapsed multiple myeloma presents a specific and unmet medical need for those living with the disease. Recently, new classes of treatments have become available, presenting new options for this difficult-to-treat disease.